Navigation Links
KV Pharmaceutical Company Announces NYSE Listing Extension
Date:12/28/2007

NYSE Agrees to a Trading Extension of KV's Securities until February 15,

2008

ST. LOUIS, Dec. 28 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology differentiated branded and generic/non-branded prescription pharmaceutical products, announced today that NYSE Regulation, Inc. has granted KV's request for a trading extension through February 15, 2008 for its securities, subject to ongoing reassessment. The extension was required under the NYSE's rules because the Company has been delayed in filing its fiscal 2007 Annual Report on Form 10-K. The Company expects to have all outstanding quarterly and annual SEC reports for fiscal 2007 filed with the SEC by February 15, 2008

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology-distinguished products through ETHEX Corporation, a national leader in pharmaceuticals that compete with branded products, and Ther-Rx Corporation, its branded prescription pharmaceutical subsidiary.

For further information about KV Pharmaceutical Company, please visit the Company's corporate website at http://www.kvpharmaceutical.com.

Safe Harbor

The information in this release may contain various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include assumptions concerning KV's operations, future results and prospects. Such statements may be identified by the use of words like "plans", "expect", "aim", "believe", "projects", "anticipate
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...K, Nov. 21 The general membership ...induct three new individuals at their Annual,Awar...re hotel in New York. A,Lifetime Achievement Awar...into the Medical Advertising Hall of Fame are: , ...r with an account position,at Sudler & Hennes...
(Date:11/21/2008)...ound 2 popular drugs do not cause genetic damage t... 21 (HealthDay News) -- Two popular medications fo...r (ADHD) do not cause genetic damage linked to an ...says. , The study, done by researchers at Duke ...tes of Health, counters a previous one that report...
(Date:11/21/2008)... Nov. 21 In a statewide survey, 33...Institute for Surgery at Presbyterian Hospital of ... annual listing of " Super Doctors ." , , E...ith Key Professional Media, Inc. to survey more th...f Texas to ask, "If you needed medical care, which...
(Date:11/21/2008)... Ind., Nov. 21 Symmetry ... provider of products to the global orthopedic dev...today that Brian S. Moore, President and Chief Exe...ident and Chief Financial Officer, are scheduled t...Care Conference at The New York Palace Hotel on We...
Breaking Medicine News(10 mins):Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2
...he Food and Drug Administration cracked down on In...d lip balm, declaring them illegal and ordering th...ops in particular pose a risk to children because ...e quantity of nicotine could be potentially danger...
...ccording to a research, women who live at high alt...heir conclusions after finding lower concentration... health and youthfulness, in women living in the m...ers looked at a control group of 160 women of simi...
...ccording to a new study taking cholesterol-lowerin... of peripheral neuropathy. Previous research has s...lesterol levels. However, researchers in Texas now...k of peripheral neuropathy, a condition marked by ...
...ccording to a new review of the medical proof, the... of venous leg ulcers. Venous leg ulcers are cause...ong people aged 60 or over. Standard treatment is ...p to a third of people still have unhealed ulcers ...
Other Medicine News:Health News:High Altitude ‘Speeds up ageing process 2
(Date:11/19/2008)... report basic findings on critical enzyme,s regula...reat an array of disorders , , MEMPHIS, Ten... at St. Jude Children,s Research Hospital have gai...y,s enzyme workhorses called calpains. , , ...unction in many cellular processes, including the ...
(Date:11/19/2008)...19 Isogen, a contract development ...g, today announced the first,phase launch of its ...to,specifically address the process, facility and...2 billion highly-niched, low-volume clinical and,...ent. , Companies can invest over $100 milli...
(Date:11/18/2008)... NeuroDiscovery Ltd (ASX... and drug development Company,and Sosei Group Co...ading,international biopharmaceutical company, to...rther pivotal pre-clinical efficacy data for NSL-0...l therapy for neuropathic pain and has,successful...
(Date:11/18/2008)...18 Arlington Medical Resources (AM... the pharmaceutical and diagnostic,imaging indust... Privigen was,sold in the U.S. during the third q...ntravenous immune globulin (IVIG) and was launched...created from the blood plasma of thousands,of don...
Breaking Medicine Technology:New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Isogen Launches Major New Facility to Address Global Biopharma Demand 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 250 Million Pound Challenge Teams Up With Churches to Spread the Gospel of Healthy Living 10345 150 Million Pound Challenge Teams Up With Churches to Spread the Gospel of Healthy Living 10345 250 Million Pound Challenge Teams Up With Churches to Spread the Gospel of Healthy Living 10345 350 Million Pound Challenge Teams Up With Churches to Spread the Gospel of Healthy Living 10345 4SoluLinK Introduces ChromaLink 28TM 29 Biotin Labeling Kit to Biotinylate and Measure With One Reagent 2822 1SoluLinK Introduces ChromaLink 28TM 29 Biotin Labeling Kit to Biotinylate and Measure With One Reagent 2822 2Prison study to investigate link between diet and behavior 2042 1Prison study to investigate link between diet and behavior 2042 2Carbon monoxide may cause long lasting heart damage 2038 1Carbon monoxide may cause long lasting heart damage 2038 2
...mboEmbolism (VTE) is Reduced by a,Significant 43% ...xane(R) / Lovenox(R), BRIDGEWATER, N.J., April 20,...ounced the publication of the PREVAIL (Prevention,...parin) trial in,the April 21st issue of The Lancet...administration of Clexane(R) / Lovenox(R),(enoxapa...
... 23, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB...ectious disease and dermatology, today announced t...ompany,s antimicrobial,compounds: CSA-8 and CSA-13...rnal of Antimicrobial Agents and Chemotherapy, a,p...ety of,Microbiology, dedicated to advances in the ...
Other Medicine Technology:The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 2The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 3The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 4The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 5The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 6Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 2Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 3Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 4
The LH 755 simplifies and automates high-volume hematology testing by integrating expert automation and advanced technologies into one workcell. It delivers reliable, accurate results every time. Plu
Kinetic and endpoint methods for the quantitative determination of creatinine in serum.
For the quantitative determination of creatine kinase-MB in serum. Kinetic Reaction measured at 340 nm. Linearity: 700 IU/L at 37C.
Intended for the quantitative determination of magnesium in serum. Wavelength: 340 nm. Linearity: 9.7 mg/dL (4 mmol/L). Two vials, dry powder reagents.
Medicine Products: